Alnylam Pharma (ALNY) Announces Planned Retirement of CEO John Maraganore
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
CEO Departure Likely to Pressure Alnylam (ALNY) Stock, M&A Possibility Will Likely Fade - Analyst
October 28, 2021 8:41 AM EDTEarlier today, alongside its Q3 report, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced the planned CEO transition of John Maraganore, Ph.D., to Yvonne Greenstreet, at... More
Alnylam Pharma (ALNY) Announces Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran
October 27, 2021 4:00 PM EDTAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of the polyneuropathy associated with hereditary transthyretin-mediated (hATTR) amyloidosis, met all secondary endpoints measured at 18 months, including statistically significant improvements in neuropathy as measured by the... More
